...
首页> 外文期刊>Cancer biology & therapy >Genomewide mRNA profiling of esophageal squamous cell carcinoma for identification of cancer biomarkers.
【24h】

Genomewide mRNA profiling of esophageal squamous cell carcinoma for identification of cancer biomarkers.

机译:食管鳞状细胞癌的全基因组mRNA谱分析,用于鉴定癌症生物标志物。

获取原文
获取原文并翻译 | 示例
           

摘要

Cancer of the esophagus is of two main types, each with distinct etiological and pathological characteristics. Esophageal squamous cell carcinoma (ESCC) is predominant type of esophageal cancers worldwide comprising almost 95% of cases. While ESCC is prevalent in the developing world, esophageal adenocarcinoma is commonly seen in the developed country, usually in association with Barrett's esophagus. In spite of its higher prevalence, ESCC has not been studied as intensively as esophageal adenocarcinoma. ESCC and esophageal adenocarcinoma are common cancers worldwide with poor survival rate among patients mainly because both of these cancers lack early biomarkers of identification. Molecular mechanisms contributing to initiation and progression of esophageal squamous cell carcinoma are still poorly understood. Development of DNA microarray technology allows high-throughput identification of gene expression profiles in cancers. In order to identify molecules as candidates for early diagnosis and/or as therapeutic targets, we analyzed the mRNA expression profiles of 20 cases of ESCC using whole genome DNA microarrays. A total of 2,235 genes were differentially regulated in the tumors as compared to the corresponding adjacent normal epithelium of which 881 were significantly upregulated. We validated two molecules that were not previously reported to be overexpressed in ESCC, oral cancer overexpressed 2 (ORAOV2) and fibroblast activation protein (FAP), by immunohistochemical labeling of tissue microarrays and archival tissue sections and found that they were overexpressed in 98% (116/118) and 68% (79/116) of cases, respectively. By gene enrichment analysis, we identified significant downregulation of several genes in the arachidonic acid metabolic pathway. Overall, using this approach we have identified a number of promising novel candidates that can be validated further for their potential to serve as biomarkers for ESCC.
机译:食道癌有两种主要类型,每种都有不同的病因和病理特征。食管鳞状细胞癌(ESCC)是全世界食管癌的主要类型,占病例总数的95%。尽管ESCC在发展中国家很普遍,但食管腺癌在发达国家很常见,通常与巴雷特食管有关。尽管ESCC的患病率较高,但并未像食管腺癌那样进行深入研究。食管鳞癌和食管腺癌是世界范围内常见的癌症,患者生存率较低,主要是因为这两种癌症都缺乏早期的生物识别标志物。尚不清楚引起食管鳞状细胞癌发生和发展的分子机制。 DNA微阵列技术的发展允许高通量鉴定癌症中的基因表达谱。为了鉴定分子作为早期诊断的候选者和/或作为治疗靶标,我们使用全基因组DNA微阵列分析了20例ESCC的mRNA表达谱。与相应的相邻正常上皮中的881个显着上调相比,共有2235个基因在肿瘤中受到差异调节。我们通过对组织微阵列和档案组织切片进行免疫组织化学标记,验证了先前在ESCC中未曾过表达的两种分子,口腔癌过表达2(ORAOV2)和成纤维细胞活化蛋白(FAP),发现它们在98%中过表达( 116/118)和68%(79/116)的案例。通过基因富集分析,我们确定了花生四烯酸代谢途径中几个基因的显着下调。总体而言,使用这种方法,我们已经鉴定出许多有前途的新候选物,这些候选物可以用作ESCC生物标志物的潜力得到进一步验证。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号